Gilmore O’Neill, Editas Medicine CEO

Ed­i­tas halts lead CRISPR pro­gram af­ter ef­fi­ca­cy da­ta un­der­whelm

Ed­i­tas Med­i­cine will put a wrap on its lead clin­i­cal pro­gram af­ter re­port­ing dis­ap­point­ing re­sults from a Phase I/II tri­al.

The biotech, one of the first to try to use CRISPR gene edit­ing tech to de­vel­op new drugs, said Thurs­day morn­ing that on­ly three of 14 pa­tients re­spond­ed to the ther­a­py, known as ED­IT-101. Ex­ecs will try to find a part­ner for the pro­gram, which is de­signed to treat an in­her­it­ed form of blind­ness called CEP290-me­di­at­ed LCA10.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.